A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)

被引：0
|
作者：
Palou, J. [1 ]
Marcq, G. [2 ]
Steinberg, G. [3 ]
Toscone, C. [4 ]
Sullivan, J. [4 ]
Linback, T. [4 ]
Pruthi, R. [4 ]
Bryce, R. [4 ]
Brown, G. [5 ]
机构：
[1] Fundacio Puigvert, Dept Urol, Barcelona, Spain
[2] CHU Lille, Urol, Ctr Hosp Reg Univ Lille, Lille, France
[3] Rush Univ, Urol, Coll Med, Chicago, IL USA
[4] EnGene Inc, Clin Dev, Waltham, MA USA
[5] Summit Hlth Jefferson Hlth New Jersey, Urol Dept, Voorhees, NJ USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2023TiP
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [41] Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
    Broughton, Edward, I
    Gooden, Kyna M.
    Mycock, Katie L.
    Rajkovic, Ivana
    Taylor-Stokes, Gavin
    BMC UROLOGY, 2022, 22 (01)
  • [42] Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21
    Pandha, H. S.
    Annels, N.
    Arif, M.
    Mostafid, H.
    Sandhu, S.
    Harrington, K.
    Melcher, A.
    Mansfield, D.
    Au, G.
    Grose, M.
    Karpathy, R.
    Shafren, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.
    Pandha, Hardev S.
    Annels, Nicola E.
    Simpson, Guy
    Mostafid, Hugh
    Harrington, Kevin J.
    Melcher, Alan
    Grose, Mark
    Davies, Bronwyn
    Au, Gough Geoffrey
    Karpathy, Roberta
    Shafren, Darren
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
    Hahn, Noah M.
    Chang, Sam S.
    Meng, Maxwell
    Shore, Neal D.
    Konety, Badrinath R.
    Steinberg, Gary D.
    Gschwend, Juergen E.
    Nishiyama, Hiroyuki
    Redorta, Juan Palou
    Taylor, John Arthur
    Elegbe, Ayanbola
    Lambert, Alexandre
    Zhu, Li
    Ishii, Yuko
    Maeda, Toshiki
    Raybold, Bradley
    Grossfeld, Gary
    Fischer, Bruce S.
    Rutstein, Mark
    Witjes, Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RaFc superagonist N-803 plus BCG.
    Chamie, Karim
    Chang, Sam S.
    Kramolowsky, Eugene V.
    Gonzalgo, Mark L.
    Lechpammer, Stanislav
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [46] A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER
    DeCastro, G. Joel
    Anderson, Christopher
    Kates, Max
    Buckley-Matura, Bridget
    Sui, Wilson
    Lee, Shing M.
    Holder, Dara
    Virk, Renu
    Drake, Charles
    Abate-Shen, Cory
    McKiernan, James
    JOURNAL OF UROLOGY, 2019, 201 (04): : E623 - E623
  • [47] ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
    Drupad, Annapureddy
    Jacob, Taylor
    Jeffrey, Howard
    Solomon, Woldu L.
    Yair, Lotan
    Shen, Tan Wei
    Ashish, Kamat
    Ian M, McElree
    Vignesh, Packiam T.
    Michael, O'Donnell
    Davaro, Facundo
    Roger, Li
    Kendrick, Yim
    Mark, Preston A.
    Stephen, Harrington
    Elizabeth, Dyer
    Jay, Raman
    Anna, Black
    Peter, Black
    Pratik, Kanabur
    Seth, Lerner
    Mathieu, Roumiguie
    Gary, Steinberg
    William, Huang
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S52 - S53
  • [48] TRIALS IN PROGRESS: A PHASE I/II TRIAL OF INTRAVESICAL CHEMOIMMUNOTHERAPY WITH GEMCITABINE AND BACILLUS CALMETTE-GUERIN (BCG) FOR PATIENTS WITH BCG-EXPOSED HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Gaffney, Christopher
    D'Souza, Neeta
    Hernandez, Christian
    McCarter, Melissa
    Moran, Patricia
    Staci, Kristen
    Worth, Kara
    Dalbagni, Guido
    Donahue, Timothy
    Donat, Sherri
    Bochner, Bernard
    Sarungbam, Judy
    Bajorin, Dean
    AL-Ahmadie, Hikmat
    Sjoberg, Daniel
    Goh, Alvin
    Pietzak, Eugene
    JOURNAL OF UROLOGY, 2023, 209 : E876 - E876
  • [49] A phase 1 study of IO102-IO103 vaccine plus pembrolizumab in patients with BCG-intolerant or unresponsive non-muscle invasive bladder cancer (NMIBC).
    Veeravelli, Sumana
    Dall'era, Marc
    Gulati, Shuchi
    Mitsiades, Nicholas
    Verma, Rashmi
    Evans, Christopher P.
    Chandrasekar, Thenappan
    Monjazeb, Arta Monir
    Lara, Primo N.
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS716 - TPS716
  • [50] Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
    DeCastro, Guarionex Joel
    Anderson, Christopher B.
    Abate-Shen, Cory
    Gray, Jillian
    Ingram, Justin
    Stein, Mark N.
    McKiernan, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345